1. HBW Insight
  2. >>Health
  3. >>Rx-to-OTC Switch

Sanofi Counts On OTC Switches Adding $1bn In Consumer Revenues By 2026

 
• By Eileen Francis

Sanofi eyes $1bn top line growth from OTC switches of ED drug Cialis and flu drug Tamiflu after they launch by 2026, says CEO Paul Hudson. Like switch consultants, though, he acknowledges the high bar for approval moving additional Rx ingredients to OTC.

Lyon France, 3 October 2017: White logo of the french multinational pharmaceutical company Sanofi on their glass office building in Lyon France - Image

Sanofi has expectations for its standalone consumer health care business to launch OTC switches of erectile dysfunction treatment Cialis and flu remedy Tamiflu by 2026 and add around $1bn to the French pharma's top line, says CEO Paul Hudson.

During the firm’s investor day on 10 December in Cambridge, MA, Hudson noted a more nimble structure for the consumer business, unshackled from the Sanofi's Rx division, will expedite developing switch applications for Cialis (tadalafil) and Tamiflu (oseltamivir). He said both should be approved for OTC sales and launched between 2023 and 2026

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Rx-to-OTC Switch

Over The Counter: Everything You Wanted To Know About Real World Evidence, With IQVIA’s Volker Spitzer

 
• By David Ridley

HBW Insight finds out all about real world evidence and its potential for the OTC industry by chatting with IQVIA Consumer Health's vice president of global research and development and real-world evidence services, Volker Spitzer.

Trump Order To Improve Making More Drugs Available OTC Puts Wind Behind Petros’ ACNU Sails

 
• By Malcolm Spicer

Petros will incorporate into its platform an analytics firm’s automated document capture and authentication system leveraging its global ID library to verify identity and eligibility of consumers accessing the self-selection process for an ACNU switch.

Melatonin And Buccal Acyclovir On German Switch Committee Agenda

 
• By David Ridley

An application for melatonin as an OTC medicine is on the agenda for the next German switch committee meeting, despite the hormone being widely available in food supplements. Acyclovir as a buccal tablet and second-generation antihistamine rupatadine are also up for discussion.

Access To Discounted Naloxone In California Expanded To All Consumers With Potential Need

 
• By Adam Zamecnik

After the product’s initial launch in May 2024, California’s government has now expanded the availability of its CalRx-branded generic OTC Narcan to all of its citizens.

More from Health